CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. (CALC) filed a Form 4 reporting new stock-option grants to director and 10% owner Fred A. Middleton. On 06/24/2025 Mr. Middleton was awarded a total of 46,249 director stock options across four separate grants. Three grants carry an exercise price of $1.53 per share and one carries an exercise price of $1.65. All options expire in 2035, providing a 10-year+ exercise window.
The largest tranche—19,687 options—vests in equal monthly installments (1/9) over the year following 01-Apr-2025. Two additional tranches of 10,000 and 6,562 options vest 1/12 monthly after 26-Mar-2025 or are immediately exercisable, respectively. The final grant of 10,000 options vests 1/12 monthly after 24-Jun-2025, but will be fully vested no later than the company’s 2026 annual meeting. All awards were approved by the board on 23-Apr-2025 and became effective after shareholder approval of the amended 2023 Equity Incentive Plan on 24-Jun-2025.
No shares were sold or otherwise disposed of; the transactions are coded “A” (grant). Post-transaction, Mr. Middleton directly holds the same number of options as were granted, reflecting his continued insider ownership. Because the filing reports only option grants and no cash transactions, the immediate impact is limited to potential future dilution and enhanced alignment of director incentives with shareholder value.
CalciMedica, Inc. filed a Form S-8 on 24 June 2025 to register additional shares of its common stock for issuance under two existing employee benefit plans: the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan. The filing relies on General Instruction E, incorporating the company’s prior S-8 registrations from 2023 and 2024. Standard exhibits accompany the statement, including legal opinions, auditor consent, governing documents, and plan materials. CalciMedica is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. Signatures include CEO A. Rachel Leheny, Ph.D., CFO Stephen Bardin, and the full board of directors.